Table 2.
Clinicopathological characteristics of patients with EOCRC
| LO-PCRC | EO-PCRC |
P valuea (LO-PCRC vs. EO-PCRC) |
LO-SCRC | EO-SCRC |
P valuea (LO-SCRC vs. EO-SCRC) |
P valuea (EO-PCRC vs. EO-SCRC) |
|
|---|---|---|---|---|---|---|---|
| N = 875 | N = 257 | N = 358 | N = 64 | ||||
| Sex (%) | |||||||
| Female | 322 (36.80) | 116 (45.14) | 0.019 | 104 (29.05) | 22 (34.38) | 0.478 | 0.157 |
| Male | 553 (63.20) | 141 (54.86) | 254 (70.95) | 42 (65.62) | |||
| Family history of tumours (%) | |||||||
| No | 854 (97.60) | 244 (94.94) | 0.047 | 341 (95.25) | 58 (90.62) | 0.229 | 0.311 |
| Yes | 21 (2.40) | 13 (5.06) | 17 (4.75) | 6 (9.38) | |||
| BMI (kg/m2) (%) | |||||||
| 18.5 to 24 | 539 (61.60) | 136 (52.92) | 0.041 | 213 (59.50) | 39 (60.94) | 0.639 | 0.257 |
| < 18.5 | 75 (8.57) | 29 (11.28) | 39 (10.89) | 9 (14.06) | |||
| ≥ 24 | 261 (29.83) | 92 (35.80) | 106 (29.61) | 16 (25.00) | |||
| Hemoglobin (g/L) (%) | |||||||
| > 110 | 630 (72.00) | 174 (67.70) | 0.209 | 223 (62.29) | 36 (56.25) | 0.439 | 0.115 |
| ≤ 100 | 245 (28.00) | 83 (32.30) | 135 (37.71) | 28 (43.75) | |||
| Platelet counts (109/L) (%) | |||||||
| ≤ 300 | 661 (75.54) | 172 (66.93) | 0.008 | 254 (70.95) | 35 (54.69) | 0.015 | 0.092 |
| > 300 | 214 (24.46) | 85 (33.07) | 104 (29.05) | 29 (45.31) | |||
| WBC (109/L) (%) | |||||||
| ≤ 10 | 817 (93.37) | 236 (91.83) | 0.475 | 330 (92.18) | 58 (90.62) | 0.864 | 0.953 |
| > 10 | 58 (6.63) | 21 (8.17) | 28 (7.82) | 6 (9.38) | |||
| CEA (ng/mL) (%) | |||||||
| ≤ 10 | 645 (73.71) | 215 (83.66) | 0.001 | 249 (69.55) | 48 (75.00) | 0.465 | 0.153 |
| > 10 | 230 (26.29) | 42 (16.34) | 109 (30.45) | 16 (25.00) | |||
| CA199 (kU/L) (%) | |||||||
| ≤ 27 | 701 (80.11) | 204 (79.38) | 0.864 | 278 (77.65) | 42 (65.62) | 0.056 | 0.031 |
| > 27 | 174 (19.89) | 53 (20.62) | 80 (22.35) | 22 (34.38) | |||
| CA125 (kU/L) (%) | |||||||
| ≤ 35 | 806 (92.11) | 239 (93.00) | 0.739 | 329 (91.90) | 54 (84.38) | 0.093 | 0.052 |
| > 35 | 69 (7.89) | 18 (7.00) | 29 (8.10) | 10 (15.62) | |||
| CA153 (kU/L) (%) | |||||||
| ≤ 25 | 860 (98.29) | 251 (97.67) | 0.700 | 354 (98.88) | 61 (95.31) | 0.126 | 0.550 |
| > 25 | 15 (1.71) | 6 (2.33) | 4 (1.12) | 3 (4.69) | |||
| AFP (ng/mL) (%) | |||||||
| ≤ 7 | 843 (96.34) | 243 (94.55) | 0.272 | 347 (96.93) | 55 (85.94) | 0.001 | 0.034 |
| > 7 | 32 (3.66) | 14 (5.45) | 11 (3.07) | 9 (14.06) | |||
| Type of ascites (%) | |||||||
| No | 816 (93.26) | 248 (96.50) | 0.157 | 330 (92.18) | 59 (92.19) | 0.745 | 0.208 |
| Serous | 52 (5.94) | 8 (3.11) | 25 (6.98) | 5 (7.81) | |||
| Bloody | 7 (0.80) | 1 (0.39) | 3 (0.84) | 0 (0.00) | |||
| Tumor location (%) | |||||||
| Right colon | 178 (20.34) | 62 (24.12) | 0.405 | 65 (18.16) | 16 (25.00) | 0.539 | < 0.001 |
| Left colon | 266 (30.40) | 77 (29.96) | 82 (22.91) | 11 (17.19) | |||
| Rectum | 431 (49.26) | 118 (45.91) | 94 (26.26) | 16 (25.00) | |||
| Multiple segment | – | – | 117 (32.68) | 21 (32.81) | |||
| Radical or palliative surgery (%) | |||||||
| Radical | 771 (88.11) | 237 (92.22) | 0.082 | 310 (86.59) | 51 (79.69) | 0.210 | 0.007 |
| Palliative | 104 (11.89) | 20 (7.78) | 48 (13.41) | 13 (20.31) | |||
| (y)pTNM staging (%) | |||||||
| 0–I | 117 (13.37) | 37 (14.40) | 0.214 | 46 (12.85) | 5 (7.81) | 0.129 | < 0.001 |
| II | 336 (38.40) | 106 (41.25) | 110 (30.73) | 20 (31.25) | |||
| III | 292 (33.37) | 89 (34.63) | 133 (37.15) | 19 (29.69) | |||
| IV | 130 (14.86) | 25 (9.73) | 69 (19.27) | 20 (31.25) | |||
| Number of retrieved lymph nodes (%) | |||||||
| < 12 | 760 (86.86) | 233 (90.66) | 0.127 | 334 (93.30) | 62 (96.88) | 0.415 | 0.169 |
| ≥ 12 | 115 (13.14) | 24 (9.34) | 24 (6.70) | 2 (3.12) | |||
| Gross classification (%) | |||||||
| Mass type | 324 (37.03) | 91 (35.41) | 0.763 | 141 (39.39) | 27 (42.19) | 0.395 | 0.064 |
| Infiltration type | 6 (0.69) | 1 (0.39) | 4 (1.12) | 2 (3.12) | |||
| Ulceration type | 545 (62.29) | 165 (64.20) | 213 (59.50) | 35 (54.69) | |||
| Histological type (%) | |||||||
| Classical adenocarcinoma | 829 (94.74) | 232 (90.27) | 0.001 | 333 (93.02) | 58 (90.62) | 0.583 | 0.675 |
| Mucinous adenocarcinoma | 46 (5.26) | 22 (8.56) | 23 (6.42) | 6 (9.38) | |||
| Signet ring cell carcinoma | 0 (0.00) | 3 (1.17) | 2 (0.56) | 0 (0.00) | |||
| Differentiation grade (%) | |||||||
| Well differentiated | 129 (14.74) | 42 (16.34) | 0.163 | 46 (12.85) | 13 (20.31) | 0.143 | 0.557 |
| Moderately differentiated | 632 (72.23) | 171 (66.54) | 255 (71.23) | 38 (59.38) | |||
| Poorly differentiated | 114 (13.03) | 44 (17.12) | 57 (15.92) | 13 (20.31) | |||
| Vessel invasion (%) | |||||||
| Negative | 735 (84.00) | 220 (85.60) | 0.600 | 287 (80.17) | 52 (81.25) | 0.976 | 0.502 |
| Positive | 140 (16.00) | 37 (14.40) | 71 (19.83) | 12 (18.75) | |||
| Neural invasion (%) | |||||||
| Negative | 695 (79.43) | 209 (81.32) | 0.564 | 289 (80.73) | 50 (78.12) | 0.755 | 0.687 |
| Positive | 180 (20.57) | 48 (18.68) | 69 (19.27) | 14 (21.88) | |||
| Ki67 expression (%) | |||||||
| Low | 48 (5.49) | 19 (7.39) | 0.469 | 23 (6.42) | 5 (7.81) | 0.680 | 0.982 |
| Moderate | 114 (13.03) | 30 (11.67) | 53 (14.80) | 7 (10.94) | |||
| High | 713 (81.49) | 208 (80.93) | 282 (78.77) | 52 (81.25) | |||
| MMR status (%) | |||||||
| pMMR | 837 (95.66) | 217 (84.44) | < 0.001 | 321 (89.66) | 49 (76.56) | 0.006 | 0.190 |
| dMMR | 38 (4.34) | 40 (15.56) | 37 (10.34) | 15 (23.44) | |||
| Alive status (%) | |||||||
| Alive | 718 (82.06) | 237 (92.22) | < 0.001 | 283 (79.05) | 55 (85.94) | 0.271 | 0.185 |
| Death | 157 (17.94) | 20 (7.78) | 75 (20.95) | 9 (14.06) | |||
aThe bolded P value was statistically significant (P < 0.05)